Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
for Patients With Non-Small Cell Lung Cancer
31 locations incl. Beverly Hills
Sponsor: OSE Immunotherapeutics
Sex: All·Age: 18+
Code: NCT06472245·Phase 3·Recruiting·Listed Jun 2024